The immune landscape of SARS-CoV-2-associated Multisystem Inflammatory Syndrome in Children (MIS-C) from acute disease to recovery
© 2021 The Authors..
Multisystem inflammatory syndrome in children (MIS-C) is a life-threatening disease occurring several weeks after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Deep immune profiling showed acute MIS-C patients had highly activated neutrophils, classical monocytes and memory CD8+ T-cells, with increased frequencies of B-cell plasmablasts and double-negative B-cells. Post treatment samples from the same patients, taken during symptom resolution, identified recovery-associated immune features including increased monocyte CD163 levels, emergence of a new population of immature neutrophils and, in some patients, transiently increased plasma arginase. Plasma profiling identified multiple features shared by MIS-C, Kawasaki Disease and COVID-19 and that therapeutic inhibition of IL-6 may be preferable to IL-1 or TNF-α. We identified several potential mechanisms of action for IVIG, the most commonly used drug to treat MIS-C. Finally, we showed systemic complement activation with high plasma C5b-9 levels is common in MIS-C suggesting complement inhibitors could be used to treat the disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
iScience - 24(2021), 11 vom: 19. Nov., Seite 103215 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Syrimi, Eleni [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Genomics |
|---|
| Anmerkungen: |
Date Revised 07.11.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.isci.2021.103215 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331732424 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331732424 | ||
| 003 | DE-627 | ||
| 005 | 20231225214116.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.isci.2021.103215 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1105.xml |
| 035 | |a (DE-627)NLM331732424 | ||
| 035 | |a (NLM)34632327 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Syrimi, Eleni |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The immune landscape of SARS-CoV-2-associated Multisystem Inflammatory Syndrome in Children (MIS-C) from acute disease to recovery |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 07.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 The Authors. | ||
| 520 | |a Multisystem inflammatory syndrome in children (MIS-C) is a life-threatening disease occurring several weeks after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Deep immune profiling showed acute MIS-C patients had highly activated neutrophils, classical monocytes and memory CD8+ T-cells, with increased frequencies of B-cell plasmablasts and double-negative B-cells. Post treatment samples from the same patients, taken during symptom resolution, identified recovery-associated immune features including increased monocyte CD163 levels, emergence of a new population of immature neutrophils and, in some patients, transiently increased plasma arginase. Plasma profiling identified multiple features shared by MIS-C, Kawasaki Disease and COVID-19 and that therapeutic inhibition of IL-6 may be preferable to IL-1 or TNF-α. We identified several potential mechanisms of action for IVIG, the most commonly used drug to treat MIS-C. Finally, we showed systemic complement activation with high plasma C5b-9 levels is common in MIS-C suggesting complement inhibitors could be used to treat the disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Genomics | |
| 650 | 4 | |a Immune response | |
| 650 | 4 | |a Immune system disorder | |
| 650 | 4 | |a Immunology | |
| 700 | 1 | |a Fennell, Eanna |e verfasserin |4 aut | |
| 700 | 1 | |a Richter, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Vrljicak, Pavle |e verfasserin |4 aut | |
| 700 | 1 | |a Stark, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Ott, Sascha |e verfasserin |4 aut | |
| 700 | 1 | |a Murray, Paul G |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Abadi, Eslam |e verfasserin |4 aut | |
| 700 | 1 | |a Chikermane, Ashish |e verfasserin |4 aut | |
| 700 | 1 | |a Dawson, Pamela |e verfasserin |4 aut | |
| 700 | 1 | |a Hackett, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Jyothish, Deepthi |e verfasserin |4 aut | |
| 700 | 1 | |a Kanthimathinathan, Hari Krishnan |e verfasserin |4 aut | |
| 700 | 1 | |a Monaghan, Sean |e verfasserin |4 aut | |
| 700 | 1 | |a Nagakumar, Prasad |e verfasserin |4 aut | |
| 700 | 1 | |a Scholefield, Barnaby R |e verfasserin |4 aut | |
| 700 | 1 | |a Welch, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Naeem |e verfasserin |4 aut | |
| 700 | 1 | |a Faustini, Sian |e verfasserin |4 aut | |
| 700 | 1 | |a Davies, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Zelek, Wioleta M |e verfasserin |4 aut | |
| 700 | 1 | |a Kearns, Pamela |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Graham S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t iScience |d 2018 |g 24(2021), 11 vom: 19. Nov., Seite 103215 |w (DE-627)NLM285332627 |x 2589-0042 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2021 |g number:11 |g day:19 |g month:11 |g pages:103215 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.isci.2021.103215 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2021 |e 11 |b 19 |c 11 |h 103215 | ||